Ingrid joined Quantum in April 2026 and has over nine years of experience in regulatory consulting. She has led and contributed to numerous IND/CTA submissions, FDA meeting briefing packages, and regulatory strategy documents across a broad range of therapeutic modalities, including small molecules, monoclonal antibodies, and cell and gene therapies. She has experience with CMC and quality as well as clinical and regulatory strategy. Prior to Quantum, Ingrid was a consultant at a global clinical CRO headquartered in Australia, where she supported global clients advance complex development programs. She earned her Ph.D. in Chemical Engineering from the University of California, Davis.